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Arginine vasopressin regulates 
the renal immune response and 
antibacterial host defense
Urinary tract infection and pyelonephritis, which are usually 
caused by uropathogenic Escherichia coli, are common 
infectious diseases in children, young adults, and patients with 
renal transplants. Toll-like receptor 4 (TLR4), which recognizes 
lipopolysaccharide (LPS), plays a central role in initiating the 
antibacterial host response; mice exhibiting a loss-of-function 
mutation in the Tlr4 gene are unresponsive to LPS and fail to 
clear Gram-negative bacteria colonizing the lower urinary tract 
and kidneys. It was previously shown that when uropathogenic 
E. coli invade the kidneys, they bind speciﬁcally to the apical 
surface of collecting duct cells. These ﬁndings indicated that, 
like bladder epithelial cells, epithelial cells from the collecting 
duct, together with bone marrow-derived cells, play a key role 
in initiating an innate immune response in the kidney.
Collecting duct cells are a major site of water reabsorption, a 
process tightly regulated by arginine vasopressin (AVP). AVP 
also stimulates the reabsorption of NaCl mediated by the epithe-
lial sodium channel and activates Cl– conductance by the cystic 
ﬁbrosis transmembrane conductance regulator. Interestingly, chil-
dren with pyelonephritis may have increased levels of circulating 
AVP and develop polyuria with urinary concentrating defect. As 
collecting duct cells are the preferential intrarenal site of bacterial 
adhesion, Chassin et al. examined the eﬀects of AVP on the renal 
Reducing versus discontinuing 
erythropoietin at high 
hemoglobin levels
For patients with chronic kidney disease or end-stage renal 
failure and anemia, targeting a higher level of hemoglobin 
causes worse outcomes. The randomized trials supporting 
this statement have received considerable focus during the 
past year. Inter- and intrapatient variability in response to 
erythropoietic stimulating agents (ESAs) provides a level of 
complexity to the practical application of these results. A new 
retrospective study provides key correlations on how to alter 
the dosing algorithm of these agents when hemoglobin meas-
urements approach the upper limit of a targeted goal.
Weiner et al. examined the hemoglobin response to two 
different dosing algorithms that were used sequentially in 
18 dialysis units. The first dosing algorithm provided for 
a discontinuation of ESA when hemoglobin was meas-
ured at > 13.0 g/dl. Following a change in Centers for 
Medicare and Medicaid Services reimbursement in 2006, 
a second dosing algorithm was implemented to decrease 
ESA dose by 25% among those with hemoglobin measure-
ments greater than 13.0 g/dl. The dose reduction proto-
col resulted in more hemoglobin levels of at least 13.0 g/dl 
(P < 0.0001), fewer levels between 11 and 12.9 g/dl (P ≤ 
0.004), no difference in the proportion of levels less than 
11 g/dl, and more ESA administered (P < 0.0001).
The renal community needs to understand the mecha-
nism that confers the additional risk to patients with anemia 
when higher hemoglobin measurements are targeted. Is the 
risk conferred by the actual hemoglobin level, the cycling of 
hemoglobin measurements, the rate of rise of hemoglobin, or 
a toxicity related to ESAs themselves? No peer-reviewed study 
to date provides insight into this question. Until the answer 
is known, careful attention to our dosing algorithms is para-
mount to minimize the contribution of each of these poten-
tial factors. This study supports the discontinuation of ESAs 
when the upper limit of the goal range is reached. Notably, 
the package labeling for available ESAs in the United States 
has updated the goal hemoglobin to 10–12 g/dl. Although 
a notable difference exists between current therapy and the 
therapy in this contemporary data set, it probably will not 
limit the applicability of these findings to present care. This 
study is one of the few to provide guidance with respect to 
dosing of ESAs and the balance between anemia correction 
and drug safety. (J Am Soc Nephrol 2007; 18: 3184–3191; 
doi:10.1681/ASN.2007040477)
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The V2R antagonist SR121463B stimulated inflammatory response and 
promoted bacterial clearance in the kidneys of mice inoculated with 
uropathogenic E. coli. Neutrophil infiltrates (brown) in untreated (top) 
and SR121463B-treated (bottom) mice.
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innate immune response and renal bacterial clearance. They used 
primary cultured collecting duct cells and an experimental model 
of ascending urinary tract infection. They found that deamino-8-
d-arginine vasopressin (dDAVP), a pure vasopressin 2 receptor 
(V2R) agonist, inhibited TLR4-mediated nuclear factor-κB acti-
vation and chemokine secretion. The dDAVP-mediated suppres-
sion involved activation of protein phosphatase 2A and required 
an intact cystic ﬁbrosis transmembrane conductance regulator 
Cl– channel. In vivo infusion of dDAVP induced a marked fall 
in proinﬂammatory mediators and neutrophil recruitment and 
a dramatic rise in the renal bacterial burden in mice inoculated 
with uropathogenic E. coli. Conversely, administration of a V2R 
antagonist to similarly infected mice stimulated both the local 
innate response and the antibacterial host defense (Figure). These 
ﬁndings describe a novel hormonal regulation of innate immune 
cellular activation and demonstrate that AVP is a potent modulator 
of microbe-induced inﬂammation in the kidney. (J Exp Med 2007; 
204: 2837–2852; doi:10.1084/jem.20071032)
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Statins reduce the risk of 
cardiovascular disease with rare 
adverse events
Statins are eﬀective cholesterol-lowering drugs that reduce the 
risk of cardiovascular disease. In a thorough article in The Lan-
cet describing statin use, beneﬁts, safety, and adverse events, 
including eﬀects on the liver, Jane Armitage reviewed 118 related 
studies in the literature. She demonstrates that statins are a well-
tolerated and extensively studied group of drugs. She found that 
statins appear to be remarkably safe drugs when used at their 
usual doses, and their proven impact on cardiovascular disease 
risk is driving their widespread use. Armitage points out a few 
caveats, as well as the need for good-quality randomized data 
on the newer statins. Armitage also found that the recognized 
adverse eﬀects, most importantly myopathy and rhabdomyolysis, 
are rare and increase with higher doses. She explains how the risk 
of myopathy and rhabdomyolysis can be kept to a minimum by 
knowledge of potential drug interactions and the vulnerability 
of particular groups of patients. Also, she found that although 
muscle pain is common in middle-aged patients, measurement 
of creatine kinase in such patients can exclude myopathy and 
allow them to safely continue drug treatment. In conclusion, 
she states that statins are safe and well tolerated for most peo-
ple, and their widespread use can potentially improve the global 
burden of cardiovascular disease. (Lancet 2007; 370: 1781–1790; 
doi:10.1016/S0140-6736(07)60716-8)
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Polymorphism at the TNF 
superfamily gene TNFSF4 confers 
susceptibility to systemic lupus 
erythematosus
TNFRSF4 (also known as OX40) is a member of the tumor 
necrosis factor (TNF) superfamily, which is primarily expressed 
on activated CD4+ T cells. Its unique ligand, TNFSF4 (OX40L), 
has a wider distribution and is found in antigen-presenting cells 
(APCs), vascular endothelial cells, and others. Recent studies 
have shown involvement of TNFRSF4 in the pathogenesis of 
a variety of immunological abnormalities of inﬂammatory, 
autoimmune, infectious, allergic, and allotransplantation-
related diseases. Blockade of TNFRSF4–TNFSF4 interaction 
has been found to modulate some of these conditions, and the 
TNFRSF4–TNFSF4 system is believed to be a promising thera-
peutic target in immunological diseases. A variety of recent 
studies have shown a genetic component to the susceptibility of 
systemic lupus erythematosus (SLE). For example, association 
studies have identiﬁed genes including IRF5 and FCGR3B as 
potentially important.
Both TNFRSF4 and TNFSF4 are found in intervals showing 
genetic linkage with SLE. In a recent study, Graham et al. 
analyzed the signiﬁcance of this association. Using both a family-
based and a case-control study design, they found that the 
upstream region of TNFSF4 contained a single risk haplotype for 
SLE. In lymphoblastoid cell lines and peripheral blood lympho-
cytes, the haplotype was associated with increased expression of 
both cell-surface TNFSF4 (Figure) and the TNFSF4 transcript. 
The authors postulate that the increased expression of TNFSF4 
predisposes to SLE either by quantitatively augmenting T cell–
APC interaction or by inﬂuencing the functional consequences 
of T-cell activation via TNFRSF4. (Nat Genet advance online 
publication, 2 December 2007, doi:10.1038/ng.2007.47)
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FACS plots of stimulated peripheral blood lymphocytes taken from 
probands expressing (a) the undertransmitted haplotype and (b) the 
overtransmitted haplotype.
